CD Biosynsis offers high-precision HeLa Cells Gene Knock-in Services, utilizing CRISPR-Cas9 coupled with Homology-Directed Repair (HDR) to achieve stable, site-specific integration of exogenous DNA into the HeLa genome. Gene knock-in is essential for creating advanced reporter cell lines, studying protein localization, and modeling specific disease mechanisms in this widely used human cancer cell host. Since HeLa cells are aneuploid, stable integration via HDR into a specific, known genomic locus is crucial to ensure reproducible expression and avoid position effects or gene silencing associated with random transfection. We provide end-to-end service, from donor design and optimization to final clone verification, accelerating functional genomics studies and the development of high-fidelity research models.
Get a QuoteFor research applications requiring accurate, constitutive expression—such as tracking protein localization or measuring transcriptional activity—random integration is highly unreliable. Our CRISPR-Cas9/HDR platform ensures the gene of interest (GOI), such as a reporter (GFP, Luciferase) or a specific protein tag (FLAG, V5), is integrated precisely at a pre-validated genomic site (Knock-in). This process involves Cas9 inducing a double-strand break (DSB) at the target locus, which is repaired via the high-fidelity Homology-Directed Repair (HDR) pathway, utilizing a donor template. This strategy is essential for achieving clonal homogeneity and stable, reproducible expression for long-term functional assays, overcoming the genomic complexity of HeLa cells.
Safe Harbor Targeting
Targeting validated genomic loci (e.g., AAVS1, ROSA26, or highly expressed regions specific to HeLa) known for stable, constitutive expression to prevent silencing.
Endogenous Tagging
Accurate insertion of small affinity tags (e.g., HA, FLAG, V5) or fluorescent tags (e.g., GFP) at the N- or C-terminus of a native protein, creating a functional fusion under the natural promoter.
Donor Template Optimization
Design of the HDR donor plasmid/DNA template, including optimized homology arms, promoters, and selection markers, tailored for high HDR efficiency in HeLa cells.
CRISPR-Cas9 & gRNA
Use of highly active Cas9 and validated gRNAs to maximize the double-strand break rate, which is essential for initiating HDR repair.
RNP + Donor Delivery
Co-delivery of the RNP (Cas9 protein + gRNA) and the linear donor DNA template via optimized electroporation/lipofection to maximize transient expression and HDR rate.
HDR Enhancer Use
Application of chemical or molecular enhancers to temporarily suppress the competing NHEJ pathway, increasing the final yield of successful site-specific knock-in clones.
Isogenic Reporter Line Creation
Integration of fluorescent or luciferase reporters to track transcription activation, protein expression, or specific signaling pathways in high-throughput screening assays.
Protein Localization Studies
Endogenous tagging of native proteins with fluorescent markers (e.g., GFP) to visualize real-time dynamics, trafficking, and sub-cellular localization without overexpression artifacts.
Disease SNP Modeling
Introduction of precise single nucleotide changes (SNPs) or disease-associated mutations to study their functional impact on protein activity and cellular phenotype.
A precision-guided process for stable genomic integration and clonal verification.
1. Donor & gRNA Design
2. RNP & Donor Co-Delivery
3. Single Cell Cloning & Screening
4. Verification & Stable Clone Delivery
Select the optimal genomic locus (Safe Harbor or endogenous gene) for the knock-in.
Design high-specificity gRNA(s) and synthesize the HDR donor cassette with optimized homology arms, promoter, and selection marker.
Design junction PCR primers to confirm accurate site-specific integration.
Co-deliver the RNP complex (Cas9 + gRNA) and the donor template into the HeLa host line using optimized transfection/electroporation.
Culture cells in a high-HDR-rate medium with chemical enhancers.
Apply antibiotic selection or FACS sorting to enrich for cells that have successfully integrated the cassette.
Genotype verification via junction PCR and definitive sequencing across the integration site to confirm clean, precise insertion (no random integration).
Phenotypic validation of the final clone for stable expression and functionality (e.g., correct protein localization).
Delivery of the verified Master Cell Bank (MCB) or research clone and comprehensive documentation.
Guaranteed Stable Expression
Integration into stable loci ensures robust, consistent, and long-term expression, overcoming the silencing often seen with random integration in HeLa cells.
Artifact-Free Tagging
Endogenous tagging under the native promoter ensures the fusion protein is expressed at physiological levels, avoiding artifacts associated with plasmid-driven overexpression.
Precision Allele Control
Dedicated screening protocols ensure the desired modification (e.g., SNP or tag) is successfully inserted into all relevant alleles, critical for the complex HeLa genome.
High-Fidelity Research Models
Creates highly controlled, isogenic cell lines and reporter lines essential for reproducible functional genomics and drug screening assays.
1. Why is stable integration preferred over transient transfection in HeLa cells?
While HeLa cells transfect easily, transient expression is short-lived and highly variable. Stable integration (knock-in) ensures the gene is inherited by all daughter cells and expressed consistently over long passages, which is required for reliable functional studies.
2. What is the difference between exogenous and endogenous knock-in?
Exogenous knock-in inserts a cassette into a "safe harbor" locus, expressing the new gene under a new promoter. Endogenous knock-in inserts a sequence (usually a tag or mutation) directly into a native gene's locus, preserving the original promoter and physiological expression levels.
3. How do you verify site-specific integration in HeLa cells?
Verification relies on junction PCR and definitive sequencing. Primers are designed to span the junction between the HeLa genomic DNA and the newly integrated donor DNA, confirming that the insertion occurred at the intended precise location.
4. What types of reporters are commonly knocked in?
Commonly knocked-in reporters include fluorescent proteins (e.g., GFP, mCherry) for live-cell imaging, luciferase (luc) for high-throughput quantification of transcription, and specific drug resistance markers.
5. What is the role of HDR enhancers in this service?
HDR (Homology-Directed Repair) is typically inefficient. We use chemical or molecular enhancers to temporarily increase the HDR repair pathway activity relative to the competing NHEJ pathway, thus significantly boosting the yield of successful knock-in clones.
6. What input is required for a Gene Knock-in project?
We require the sequence of the gene of interest (GOI) or tag, the desired location of insertion (e.g., C-terminus of Protein X, or AAVS1 locus), and confirmation of the desired functional outcome.
7. How do you manage the aneuploidy challenge for knock-in?
For knock-in applications, we prioritize stable sites (Safe Harbors) that are less variable or ensure that if an endogenous gene is tagged, the resulting clone is functionally homogeneous, often requiring selection strategies that favor multi-allelic integration.
8. What is the benefit of endogenous tagging for protein studies?
Endogenous tagging ensures that the tagged protein is regulated, expressed, and spliced just like the native protein. This avoids artifacts caused by over-expression or mis-localization, providing the most biologically relevant model for visualization and function studies.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.